Abridge was founded in 2018 with the mission of powering deeper understanding in healthcare. Our AI-powered platform was purpose-built for medical conversations, improving clinical documentation efficiencies while enabling clinicians to focus on what matters most—their patients. Our enterprise-grade technology transforms patient-clinician conversations into structured clinical notes in real-time, with deep EMR integrations. Powered by Linked Evidence and our purpose-built, auditable AI, we are the only company that maps AI-generated summaries to ground truth, helping providers quickly trust and verify the output. As pioneers in generative AI for healthcare, we are setting the industry standards for the responsible deployment of AI across health systems.

Andes is a pioneering company that integrates beneficial microorganisms into agricultural practices to enhance carbon dioxide removal from the atmosphere while promoting crop growth. Their technology allows agricultural fields to function as carbon dioxide removal mega-factories, achieving significant carbon capture at a low cost and within a short timeframe. By leveraging naturally occurring microorganisms, Andes provides a sustainable solution that not only addresses climate change but also improves soil health and agricultural productivity. The company is positioned to make a substantial impact in the carbon removal market, appealing to environmentally conscious farmers and businesses.

Aperiam is building hyperfolding enzymes with deep learning algorithms that understand protein chemistry.

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information, visit www.azitrainc.com.

Braid Health is redefining the landscape of healthcare diagnostics with its innovative approach to real-time radiology and medical imaging. By harnessing the power of advanced technology, we provide healthcare professionals with the tools they need to deliver immediate, high-resolution diagnostic results. This not only enhances the patient experience by reducing wait times for critical information but also significantly improves the efficiency of healthcare operations. Our solutions are designed with the end-user in mind, ensuring that they can be seamlessly integrated into existing healthcare workflows without disrupting the delicate ecosystem of patient care. Whether it's for medical or dental applications, Braid Health's imaging technology is versatile and robust, enabling a level of collaboration and communication between healthcare providers that was previously unattainable. At Braid Health, we are driven by a mission to empower healthcare providers and improve patient outcomes.

Bullseye Biosciences is a biotechnology research company that operationalizes cutting-edge directed evolution technology to develop novel therapeutics for cardiometabolic, inflammation, and oncology patients. By leveraging automation and Next Generation Sequencing, they aim to address challenging drivers of human disease, positioning themselves as a leader in the biotherapeutics space. Their world-class team focuses on translating scientific advancements into effective medicines, making them a compelling option for investors interested in innovative healthcare solutions.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

Checkerspot is a biotechnology company designing materials and ingredients at a molecular level to enable more sustainable and high-performing products. By optimizing microalgae, Checkerspot’s vertically integrated WING™ platform biomanufactures unique oils that replace commodity oils and petroleum-based inputs and improve performance properties in targeted hardgoods, textiles, and personal care products.

Cirsium Biosciences is revolutionizing the gene therapy industry by developing innovative viral vector production methods using whole plants as bioreactors. Their platform addresses significant manufacturing challenges such as scalability, cost, and lead times, achieving up to a 70% reduction in manufacturing lead times for gene therapies. By utilizing a non-GMP controlled environment, they offer a cost-effective solution that simplifies the supply chain and enhances safety. With a commitment to improving global access to life-saving therapies, Cirsium is positioned as a leader in the gene therapy market, leveraging their unique plant-based production technology to meet the growing demand for viral vectors.

Curie.Bio is a founder-focused seed-stage venture capital firm that provides biotech founders with access to top drug hunters, R&D services, and capital-efficient support. With a portfolio of 20 early-stage therapeutics companies, Curie.Bio helps founders navigate the complexities of drug development, ensuring they retain agency and equity while achieving significant milestones. Their model emphasizes collaboration with experienced professionals, leveraging a vast network of CRO partnerships to enhance research capabilities and drive progress towards clinical data. This approach has proven effective, as demonstrated by their portfolio companies achieving rapid advancements and substantial funding rounds.

Cypris Materials is developing a new generation of sustainable color that broadens the color gamut while simplifying manufacturing, application, and formulation. Cypris Materials, Inc. has harnessed the transformative power of structural color - a method of producing color that has evolved over millions of years. Cypris Materials' structural coating platform helps industry-leading companies and individuals redefine the capabilities of color. Our polymers, backed by an extensive patent portfolio, unlock exclusive colors and effects that can only be achieved through our paint. Cypris’ materials enable a new paradigm: the first safe and sustainable structural color palette, free of toxic pigments and dyes.